

Fig. 1





Fig. 2



IV

Fig. 3A




Fig. 3B

SC








Fig. 4



6/12








9/12


Fig. 8



10/12

Fig. 9

A



B




Fig. 10


A CSL312 heavy chain amino acid sequence

```
1   EVQLLESGGG LVQPGGSLRL SCAASGFTFS KYIMQWVRQA PGKGLEWVSG 50
51  IDIPTKGTTVY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCARAL 100
101 PRSGYLISPH YYYYALDVWG QGTTVTVSSA STKGPSVFPL APCSRSTSES 150
151 TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG LYSLSVTV 200
201 PSSSLGTKTY TCNVDHKPSN TKVDKRVESK YGPPCPPCPA PEFLGGPSVF 250
251 LFPPKPKDTL MISRTPEVTC VVVDVSQEDP EVQFNWYVDG VEVHNAKTKP 300
301 REEQFNSTYR VVSVLTVLHQ DWLNGKEYKC KVSNGKLPSS IEKTISKAKG 350
351 QPREPQVYTL PPSQEEMTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY 400
401 KTTTPVLDSD GSFFLYSRLT VDKSRWQEGN VFSCSVMHEA LHNHYTQKSL 450
451 SLSLGK* 456
```

B CSL312 lambda light chain amino acid sequence

```
1   QSVLTQPPSA SGTPGQRVTI SCSGSSSNIG RNYVYQQL PGTAPKLLIY 50
51  SNNQRPSGVP DRFSGSKSGT SASLAISGLR SEDEADYYCA AWDASLRGVF 100
101 GGGTKLTVLG QPKAAPSVTL FPPSSEELQA NKATLVCLIS DFYPGAVTVA 150
151 WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
201 EGSTVEKTVA PTECS 215
```

Fig. 11



HAE = hereditary angioedema; OLE = open-label phase 3b study; q1M = once a month; SC = subcutaneous